Feeder cells play a critical role in enabling robust proliferation and activation of NK cells during ex vivo manufacturing. A key requirement for clinical applications is that these feeder cells must not persist in the final NK cell product administered to patients.
Our patented approach eliminates the need for irradiation of feeder cells while delivering equivalent performance. Validation studies demonstrate that NK cells expanded using these non-irradiated feeder cells exhibit: comparable proliferation rates, an identical phenotype across 16 key parameters and equivalent cytotoxicity (killing capacity) against target cells when benchmarked against those expanded with traditional irradiated feeder cells. Importantly, the final product contains no residual feeder cells.
From both logistical and regulatory standpoints, this method offers substantial advantages: it simplifies manufacturing processes, reduces handling complexities associated with irradiation, and supports more streamlined compliance and scalability for clinical-grade NK cell production.
This innovation represents a meaningful advancement in the safe and efficient generation of high-quality NK cell therapies. CiMaas remains committed to advancing next-generation immunotherapies through cutting-edge process improvements.